Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515630 · ClinicalTrials.gov registry record · Phase 2
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
A Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT02515630 is a Phase 2 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 41 participants.
The verdict
NCT02515630, a Phase 2 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).
Interventions
- DRUG MMB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-01-29 |
| Est. Completion | 2017-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02515630
The ClinicalTrials.gov registry entry for NCT02515630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MMB is the first listed.
NCT02515630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02515630 about?
NCT02515630 is a clinical study titled "Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)". This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).
What is the current status of trial NCT02515630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2016-01-29. Estimated completion is 2017-08-15.
What interventions are being tested in trial NCT02515630?
The interventions under investigation include: MMB (DRUG).
Who is sponsoring clinical trial NCT02515630?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.